Last reviewed · How we verify
Propofol Injection [Diprivan]
Propofol Injection [Diprivan] is a Small molecule drug developed by Zagazig University. It is currently FDA-approved.
At a glance
| Generic name | Propofol Injection [Diprivan] |
|---|---|
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Propofol Injection [Diprivan] CI brief — competitive landscape report
- Propofol Injection [Diprivan] updates RSS · CI watch RSS
- Zagazig University portfolio CI
Frequently asked questions about Propofol Injection [Diprivan]
What is Propofol Injection [Diprivan]?
Propofol Injection [Diprivan] is a Small molecule drug developed by Zagazig University.
Who makes Propofol Injection [Diprivan]?
Propofol Injection [Diprivan] is developed and marketed by Zagazig University (see full Zagazig University pipeline at /company/zagazig-university).
What development phase is Propofol Injection [Diprivan] in?
Propofol Injection [Diprivan] is FDA-approved (marketed).
Related
- Manufacturer: Zagazig University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing